Raymond James Financial Reaffirms Market Perform Rating for Tvardi Therapeutics (NASDAQ:TVRD)

Key Points

• Tvardi Therapeutics has been downgraded by Raymond James Financial from an "outperform" to a "market perform" rating, reflecting concerns about the company's current performance.
• Recently, other analysts have issued negative ratings and decreased target prices for the stock, with Barclays setting a target of $5.00 and BTIG Research reducing the target from $55.00 to $15.00.
• The stock has experienced a significant decline, with a reported drop of 83.9%, currently trading around $6.69, compared to a 1-year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report)'s stock had its "market perform" rating reissued by investment analysts at Raymond James Financial in a report issued on Tuesday, MarketBeat Ratings reports.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday. BTIG Research decreased their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday. Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the stock a "negative" rating in a research note on Monday. Piper Sandler lowered shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. Finally, Weiss Ratings restated a "sell (e)" rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Tvardi Therapeutics presently has an average rating of "Hold" and an average target price of $55.50.

Tvardi Therapeutics Trading Down 3.9%

Shares of TVRD stock traded down $0.26 on Tuesday, hitting $6.43. 602,064 shares of the stock traded hands, compared to its average volume of 72,207. The company's 50-day moving average price is $31.63. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Investors Weigh In On Tvardi Therapeutics

Several large investors have recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $80,000. Bank of America Corp DE acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $399,000. 683 Capital Management LLC acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $4,107,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $43,000. Finally, Slate Path Capital LP acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $16,427,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.